B2Core Reveals Its Latest Updates: What’s New?
29.5.2023 17:00:00 EEST | Business Wire | Press release
B2Core, the premier CRM solution trusted by brokers and exchanges around the globe, continues to push the boundaries of innovation with its most recent significant update. This update introduces several advanced features and streamlined operations, giving financial institutions more powerful capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005019/en/
Telegram Integration (Graphic: Business Wire)
Let's have a look at the most notable features.
1. Advanced Event Notification Module
A brand-new Event Notification module has been added to the B2Core Back Office, providing admin users with a vast array of customizable event notifications. With the available 27 choices, administrators may send out alerts for various situations, from withdrawal requests to successful registrations.
Notifications are sent out to admin users on time whenever an event occurs, allowing them to respond appropriately. Additionally, the system allows additional admin users to be added to the "Users" category to receive notifications.
For your convenience, the module's event notification channels include email, SMS, Slack, and now Telegram. The "System-Templates" tab is where administrators may adjust settings and select a notification method. All event notifications are simply accessible via the user card, ensuring that vital information is always readily available.
For additional information on the new Event Notifications module, visit the official B2Core documentation page. In addition, there is a detailed How-To Guide and the References page covering more details.
2. Telegram Integration
B2Core now supports integration with Telegram, giving users even more channels to receive alerts. To begin getting Telegram notifications, users first must link their Telegram chat ID profile to their B2Core Back Office account, which is done in the admin's card under "System – Users – Edit user."
Users may configure the appropriate template under the "System – Templates – Telegram" section after navigating to the admin's card. It is now much easier for users to get important notifications on time by adding the Telegram channel to the Event Notifications area.
Step-by-step instructions on creating a Telegram template, activating a Telegram bot, and locating your unique chat ID may be found in our comprehensive How-to articles, ensuring a seamless onboarding process.
3. Detailed cTrader Data
B2Core's cTrader account interface, recently updated, provides an unmatched amount of depth for traders. Equity, Balance, Leverage, Credit, and Free Funds are just a few indications that users may dig into for their current accounts.
In addition, users may examine graphical representations of equity indicators across different timeframes and at different scales to gain a deeper understanding of the data. Access to real-time information on user orders and open positions and extensive historical information on performed trades and other pertinent data is also easily accessible. With this intuitive interface, investors can get all the relevant trading data they need in one convenient location.
4. Simplified Bulk Deposits to Client Accounts
In response to user feedback, the latest update introduces a new feature that simultaneously simplifies the process of depositing funds into multiple accounts. Within the "Accounts" section, the "Update Balances" window allows users to add funds to various designated accounts by uploading a CSV file containing the Email, ID, and precise amount. This streamlined process eliminates manual input, saving time and effort.
Bottom Line
B2Core's latest update cements its position as the CRM solution for brokers and exchanges. Introducing the Event Notification Module, Telegram Integration, Enhanced cTrader Data, and Simplified Bulk Deposits to Client Accounts showcase B2Core's commitment to providing a comprehensive and streamlined platform. Stay tuned for more exciting new features as B2Core continues to drive innovation in the industry!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230529005019/en/
Contact information
Artyom Goryushin
+44 2080 688 636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
